Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00483184 | Low Dose Interferon Alpha Treatment for Oral Ulcers of Behcet's Disease | PHASE2 | COMPLETED | 84 | — | — | Apr 1, 2006 | Apr 1, 2008 | Jun 16, 2009 | 4 | Turkey (Türkiye) |
A patient with a 75% or greater decrease in total OU for three visits was considered a "sustained responder".
| Arm | Type | Description |
|---|---|---|
| 1 | PLACEBO_COMPARATOR | (placebo)0 IU IFNa |
| 2 | EXPERIMENTAL | (Veldona)500 IU IFNα bid |
| 3 | EXPERIMENTAL | (Veldona)1000 IU IFNα bid |
| Name | Type | Description |
|---|---|---|
| Veldona, | BIOLOGICAL | Very low dose oral natural human interferon alpha lozenges |
Inclusion Criteria: * Is a male or a non-pregnant, non-lactating female. * Has a history and clinical presentation consistent with a diagnosis of Behçet's Disease and meets International Study Group criteria (Appendix B). * Has a history of oral ulcers for at least 12 months. * Has a history of mon...